The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine

The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine

The platelet-activating factor receptor (PAFR) and its ligand (PAF) are important inflammatory mediators that are overexpressed in ovarian cancer. The receptor is an important player in ovarian cancer development. In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian...

Full description

Bibliographic Details
Main Authors: Eileen Deuster, Ivi Hysenaj, Maja Kahaly, Elisa Schmoeckel, Doris Mayr, Susanne Beyer, Thomas Kolben, Anna Hester, Fabian Kraus, Anca Chelariu-Raicu, Alexander Burges, Sven Mahner, Udo Jeschke, Fabian Trillsch, Bastian Czogalla
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cells
Subjects:
ovarian cancer
platelet-activating factor receptor (PAFR)
rupatadine
platelet-activating factor (PAF)
Online Access:https://www.mdpi.com/2073-4409/10/9/2337

Internet

https://www.mdpi.com/2073-4409/10/9/2337

Similar Items